GlassScriptPhysician profile
Madison D Walters
NPI 1770184681
$5,589.80
in general payments reported to CMS, 2019-2025
29 companies · $1,403 in 2025
The $1,403 reported for 2025 was more than what 92% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $596 · 2022: $1,088 · 2023: $1,588 · 2024: $915 · 2025: $1,403.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,906.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,905.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $877.77 | 2021-2022 | |
| Abbvie INC. | $705.10 | 2022-2025 | |
| Braeburn INC. | $666.03 | 2023-2025 | Brixadi |
| Axsome Therapeutics, INC. | $591.62 | 2023-2025 | Auvelity |
| Uswm, LLC | $577.82 | 2022-2023 | Lucemyra, Zimhi |
| Tris Pharma INC | $295.64 | 2023-2025 | Dyanavel Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $267.54 | 2022-2025 | Caplyta |
| Alkermes, INC. | $180.53 | 2021-2025 | Aristada, Lybalvi |
| Corcept Therapeutics | $178.10 | 2024-2025 | Korlym |
| Indivior INC. | $140.87 | 2023-2025 | Sublocade |
| Currax Pharmaceuticals LLC | $126.12 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $121.46 | 2024-2025 | Rexulti |
| Redhill Biopharma INC. | $103.72 | 2021 | |
| Supernus Pharmaceuticals, INC. | $102.21 | 2022-2023 | Qelbree |
| Neurocrine Biosciences, INC. | $94.43 | 2024-2025 | Ingrezza |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $78.29 | 2022 | |
| Shield Therapeutics INC | $71.50 | 2022-2024 | Accrufer |
| Biohaven Pharmaceutical Holding Company LTD. | $64.67 | 2022 | |
| Orexo US, INC. | $57.59 | 2022-2023 | Zubsolv |
| Novo Nordisk INC | $47.96 | 2023-2025 | Wegovy |
| Teva Pharmaceuticals USA, INC. | $41.43 | 2023-2025 | Austedo, Uzedy |
| Becton, Dickinson and Company | $39.67 | 2024 | Bd Onclarity |
| Biogen, INC. | $34.28 | 2025 | Zurzuvae |
| Mayne Pharma Commercial LLC | $27.47 | 2023 | |
| Amarin Pharma, INC. | $24.83 | 2021 | |
| Astellas Pharma US INC | $22.00 | 2024 | Veozah |
| Intra-Sana Laboratories | $18.80 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| E.R. Squibb & Sons, L.L.C. | $18.79 | 2025 | Cobenfy |
| Vertical Pharmaceuticals, LLC | $13.56 | 2023 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madison Walters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.